Research programme: buprenorphine intranasal - Vernalis/Reckitt Benckiser
Alternative Names: IX-1004; IX-1005; V 1004; V 1005Latest Information Update: 13 Jan 2022
Price :
$50 *
At a glance
- Originator Reckitt Benckiser; Vernalis
- Developer Vernalis
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain; Substance-related disorders
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 14 Mar 2007 Preclinical development is ongoing
- 26 Jul 2005 Ionix Pharmaceuticals has been acquired and merged into Vernalis